Immuneering Co. (NASDAQ:IMRX) Receives $13.50 Average PT from Analysts

Immuneering Co. (NASDAQ:IMRX) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $13.50.

A number of research analysts have recently commented on the stock. Mizuho reduced their price target on shares of Immuneering from $20.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Immuneering in a research report on Wednesday, May 8th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immuneering stock. Exchange Traded Concepts LLC lifted its position in Immuneering Co. (NASDAQ:IMRX) by 34.0% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 17,416 shares of the company’s stock after purchasing an additional 4,417 shares during the period. Exchange Traded Concepts LLC owned about 0.06% of Immuneering worth $128,000 as of its most recent SEC filing. 67.65% of the stock is currently owned by institutional investors.

Immuneering Stock Down 3.4 %

IMRX opened at $1.15 on Thursday. The firm has a 50-day moving average price of $1.35 and a 200-day moving average price of $3.20. Immuneering has a twelve month low of $1.05 and a twelve month high of $10.99. The company has a market capitalization of $34.10 million, a price-to-earnings ratio of -0.61 and a beta of -0.61.

Immuneering (NASDAQ:IMRX) last issued its earnings results on Tuesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.04). On average, sell-side analysts expect that Immuneering will post -1.93 earnings per share for the current fiscal year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.